Invitae Congenital Myasthenic Syndrome Panel
No-charge genetic testing for Congenital Myasthenic Syndromes (CMS), sponsored by argenx and performed by Labcorp Genetics, with free genetic counseling.
Accessed through the Congenital Myasthenic Syndromes (CMS) Sponsored Testing Program•Sponsored by argenx•Performed by Invitae | Labcorp
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
The argenx CMS Sponsored Testing Program provides a no-cost 21-gene NGS panel for patients with clinical suspicion of congenital myasthenic syndromes. Given the phenotypic heterogeneity and rarity of CMS, timely molecular confirmation enables genotype-directed management and may meaningfully alter the treatment approach. Genetic counseling services are included, and ordering carries no prescribing or purchase obligation.
When to consider this test
Patient selection
- Patient resides in the United States
- Patient has a clinical suspicion of a congenital myasthenic syndrome based on the ordering provider's medical assessment
Workflow
How to use this program
- 1
Identify eligible patients
Consider patients with suspected or confirmed ARVC, concerning arrhythmias, or relevant family history.
- 2
Order through your usual workflow
Use your standard ordering process for submitting tests to Example Genetics Lab (portal or existing workflows).
- 3
Integrate results into management
Use results to refine diagnosis, guide cascade testing, and inform monitoring and treatment decisions.
- 4
Plan follow-up and cascade testing
Determine downstream actions including surveillance, family member testing, and long-term management plans.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Invitae | Labcorp, a CLIA-certified laboratory (CLIA 05D2040778). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which patients are appropriate for the congenital myasthenic syndromes sponsored testing program?
The argenx CMS Sponsored Testing Program is intended for individuals suspected of having congenital myasthenic syndromes based on clinical features such as fatigable weakness involving ocular, bulbar, facial, axial, limb, or respiratory muscles, particularly when onset is in infancy or early childhood. CMS presentation and severity are highly heterogeneous and genotype-dependent, so a broad clinical index of suspicion may be warranted. Clinicians should confirm that patients meet the program's eligibility criteria at the time of ordering.
What does the Invitae Congenital Myasthenic Syndrome Panel cover and what methodology is used?
The Invitae Congenital Myasthenic Syndrome Panel interrogates 21 genes associated with CMS using next-generation sequencing (NGS). The panel is performed by Invitae at Labcorp. This breadth of coverage is designed to address the genetic heterogeneity underlying CMS and support genotype-informed clinical management.
What specimen types are accepted for the CMS genetic testing program?
The preferred specimen for the Invitae Congenital Myasthenic Syndrome Panel is 3 mL of whole blood collected in a purple-top EDTA tube (K2EDTA or K3EDTA). Alternate specimens including saliva, buccal swab, and extracted gDNA are also accepted. Kits can be requested through the program's ordering portal.
What is the turnaround time for the congenital myasthenic syndromes genetic panel?
The Invitae Congenital Myasthenic Syndrome Panel has a turnaround time of 10 to 21 calendar days, with an average of approximately 14 days. Results are delivered to the ordering clinician. Genetic counseling services are available at no cost through the program to support result interpretation and patient communication.
Is there any prescribing or purchase obligation when ordering through the CMS sponsored testing program?
There is no obligation whatsoever. Healthcare professionals and patients who participate in the argenx CMS Sponsored Testing Program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any products or services from argenx or Labcorp Genetics. The full cost of testing and genetic counseling is covered by argenx, the program's sponsor, at no charge to the patient or ordering provider.
Is genetic counseling available through the CMS sponsored testing program?
Yes, genetic counseling is included as part of the argenx CMS Sponsored Testing Program at no cost. Board-certified genetic counselors can support both pre-test and post-test discussions. Given the phenotypic variability and treatment implications of specific CMS subtypes, counseling can be a valuable resource for both clinicians and families navigating results.
Which patients are eligible for Congenital Myasthenic Syndromes (CMS) Congenital Myasthenic Syndromes genetic testing?
Patients may qualify for Congenital Myasthenic Syndromes (CMS) if they meet the program's eligibility criteria:
- Patient resides in the United States
- Patient has a clinical suspicion of a congenital myasthenic syndrome based on the ordering provider's medical assessment
See an issue with this program?